Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Sarepta Therapeutics, Inc. logoSarepta Therapeutics, Inc.

SRPT · Nasdaq · USD · Market cap $1.6B · 835 employees

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for…

PASS · Titan Ethical · score 70.0
13.33 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price13.33 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readDistribution, as of 16 Nov 2026
  • Ethical screenPasses, score 70.0 out of 100
  • OptionsOpen interest leans to puts (put/call 6.62)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $24.48 to $26.66, base estimate $25.00 (screen dated 2026-11-20).

Current read
Distribution ?
Undervalued · screened 2026-11-20
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 6.62, read 2026-11-20
  • Ethical passes the values gate
Price13.33 USD
Fair value25.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-19Read Distribution14.53-8.3% to today ✓Markup gives way to Distribution after a 25% slide in 3 weeks
2026-10-29Read Markup19.32-31.0% to today Distribution gives way to Markup first Markup read since September
2026-10-02Read Distribution20.14-33.8% to today ✓Markup gives way to Distribution after a 7% slide in 3 weeks
2026-09-13Read Markup21.59-38.3% to today Accumulation gives way to Markup after a 17% rise in 4 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Sarepta Therapeutics, Inc. holds its Distribution at $13.33. Consolidating, no directional conviction, held for 136 days.

As held on the ledger · 2026-11-20
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 136 days
Price at the screen$13.33
Valuation738.50 trailing · 9.96 forward price to earnings
Values screenPASS · score 70.0
Beta0.45
The Workings

Five Screens: SRPT's Results

PASS. All five recorded results clear their limits.

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 31.04% Below 33% Pass
Interest-bearing cash 4.13% Below 33% Pass
Receivables 35.81% Below 49% Pass
Revenue purity 1.67% Below 5% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Clears, in Plain English

PASS · Titan Ethical

Sarepta Therapeutics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when SRPT's ethical verdict changes

Today SRPT passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 47% discount to our $25.00 fair value.

Method.

24.48Conservative25.00Base case26.66Growth case 13.33Price

USD, 2026-11-20 screen. A 46.7% under base.

The Street's Range
5.00Street low 20.00Street average 38.00Street high 13.33Price

Street: 22 covering, consensus Hold. Average target +50%.

Chart
The Business, in Plain Words

Rare disease hopes meet shrinking revenue

Imagine families waiting on a single genetic therapy to change a child's life. Sarepta develops exactly those RNA and gene treatments for rare conditions, yet the business shows no lift. We pass because revenue is falling and the numbers offer nothing to build a case around.

Forward earnings sit at seven times but top line slipped two percent, profit margins reach only three percent and return on equity is five percent. Analysts call it a hold with a twenty dollar median target, well below our fair value mark. The ethical screen clears yet opportunity stays at none.

An unknown moat in a trial heavy field leaves the firm exposed to sudden setbacks that can wipe out years of work. Low returns and flat growth point to a business that has yet to prove durable scale. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E10.0xvery cheap relative to earnings
Trailing P/E738.5xexpensive: the price assumes strong growth ahead
EPS, trailing0.02
EPS, forward1.48
Revenue growth-4.5%revenue is shrinking
Profit margin-5.9%currently unprofitable
Return on equity-8.0%not currently earning a positive return on equity
FCF yield6.90%
Debt to equity0.71moderate, manageable leverage
Current ratio3.46comfortably covers its short-term bills
Beta0.45barely tracks the market's swings
Short interest, float0.22%
52-week range14.59 - 24.68
Market cap$1.6B
Employees835

SRPT-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Distribution $14.17 -2.5% Entry 20
2026-11-19 Distribution · changed $14.53 -12.9% Entry 19

The framework has shifted from markup to distribution since the last review. Since the last review it saw its composite score rise.

2026-11-12 Markup $16.68 -12.2% Entry 18
2026-11-05 Markup $18.99 +2.4% Entry 17
2026-11-04 Markup $18.54 +1.2% Entry 16
2026-11-03 Markup $18.32 -1.6% Entry 15
2026-11-02 Markup $18.62 +0.0% Entry 14
2026-11-01 Markup $18.62 +0.0% Entry 13
2026-10-31 Markup $18.62 -3.2% Entry 12
2026-10-30 Markup $19.23 -0.5% Entry 11

Earnings landed in this window. Ethical screening: PASS.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on SRPT

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in SRPT's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $19.40 -22.1% · $779 -22.1%
2 months $21.18 -28.7% · $713 -28.7%
3 months $17.04 -11.3% · $887 -11.3%
6 months $21.75 -30.5% · $695 -30.5%
1 year $39.07 -61.3% · $387 -61.3%
2 years $122.59 -87.7% · $123 -87.7%
3 years $127.67 -88.2% · $118 -88.2%
5 years $86.00 -82.4% · $176 -82.4%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever SRPT does next, these words stay.

Sarepta Therapeutics, Inc. · SRPT · Distribution · $13.33
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.